Oral sildenafil versus bosentan for treatment of persistent pulmonary hypertension of the newborn: a randomized controlled trial

Aditya Kallimath,Sujata Deshpande,Pari Singh,Reema Garegrat,Satyan Lakshminrusimha,Rajesh Maheshwari,Pradeep Suryawanshi

DOI: https://doi.org/10.1186/s12887-024-05107-0

2024-11-03

BMC Pediatrics

Abstract:Access to inhaled nitric oxide (iNO) is limited in low resource settings due to non-availability and high cost. There is a need for research on low-cost alternative therapies for management of persistent pulmonary hypertension of the newborn (PPHN). We aimed to compare oral sildenafil and bosentan as monotherapy in the treatment of neonates with PPHN.

pediatrics